Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer
Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer On November 23, 2017, Biocon India’s premier Biopharmaceuticals Company announced that it has launched KRABEVA®, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India 1. KRABEVA®, a monoclonal …